arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences,

FT US Healthcare & Life Sciences Summit 2016

Navigating the Shift to Value

New York |
Speakers include:
Tom Frieden

Tom Frieden

Centers for Disease Control and Prevention

Alex Gorsky

Alex Gorsky

Johnson & Johnson

Stefano Pessina

Stefano Pessina

Walgreens Boots Alliance

Overview

The US healthcare industry is in the midst of the largest transformation in its history. Silos are dissolving and synergies evolving. Organizations are partnering, affiliating and consolidating at record rates. Value based care and outcomes based pricing are becoming a reality across the industry, and various consumer and digital savvy players from the world of retail and food to consumer electronics are entering the healthcare realm and transforming the competitive landscape of the industry. How will the future unfold?

Bringing together providers, payers, industry executives, patient representatives and investors, Financial Times Live is pleased to present the FT US Healthcare & Life Sciences Summit. With a focus on emerging industry trends, this timely event will highlight the challenges and opportunities that market disruptions, political changes and digital innovations will create for the healthcare and life sciences industry.

fallback
fallback Add to my Calendar 05/12/2016 08:00:0005/12/2016 16:25:00trueFT US Healthcare & Life Sciences Summit 2016The US healthcare industry is in the midst of the largest transformation in its history. Silos are dissolving and synergies evolving. Organizations are partnering, affiliating and consolidating at record rates. Value based care and outcomes based pricing are becoming a reality across the industry, and various consumer and digital savvy players from the world of retail and food to consumer electronics are entering the healthcare realm and transforming the competitive landscape of the industry. How will the future unfold?Bringing together providers, payers, industry executives, patient representatives and investors, Financial Times Live is pleased to present the FT US Healthcare & Life Sciences Summit. With a focus on emerging industry trends, this timely event will highlight the challenges and opportunities that market disruptions, political changes and digital innovations will create for the healthcare and life sciences industry.FT-US-Healthcare-&-Life-Sciences-Summit-20168c749d3ee38e6ebb5b4895720bc643eeMM/DD/YYYY

Brochure downloads

Brochure Download

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

Data Protection

By submitting this form you consent to being contacted by FT Live about this event by phone and email.

Thank you for submitting your details. Please download the event brochure.

Untitled Block

"I felt heartened to hear patient quality of life, extension of health, and general respect for the patient journey play so prominently in the mindset of the panelists."
- Melissa Lee, Interim Executive Director, Diabetes Hand Foundation

“I continue to be blown away by the high-level of your conferences...the content is superb.”
- Laurence Gottlieb, President and CEO, Hudson Valley Economic Development Corporation

fallback

Speakers (26)

Tom Frieden

Tom Frieden

Director
Centers for Disease Control and Prevention

Tom Frieden is Director of the Centers for Disease Control and Prevention (CDC). Since 2009, Dr Frieden has intensified CDC’s work to protect the health, safety and security of the American people, including leading the agency’s response to the recent Ebola epidemic and other health emergencies. Under his direction, new CDC programs have focused on combating antibiotic resistance, preventing foodborne and healthcare-associated infections, helping people quit smoking, addressing the prescription drug overdose epidemic, and advancing global health security worldwide. Dr Frieden previously led New York City's program that cut multidrug-resistant tuberculosis by 90 percent, and helped India prevent more than 3 million tuberculosis deaths. As New York City's Health Commissioner from 2002 to 2009, he helped reduce teen smoking by half and adult smoking by one-third. Dr Frieden received his Medical and Master's of Public Health degrees from Columbia University. He completed infectious disease training at Yale University.

Alex Gorsky

Alex Gorsky

Chairman of the Board and CEO
Johnson & Johnson

Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson. He began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988.  Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management.  In 2001, he was appointed President of Janssen, and in 2003, he was named Company Group Chairman of Johnson & Johnson’s pharmaceuticals business in Europe, the Middle East and Africa. 

Mr Gorsky left Johnson & Johnson in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company’s pharmaceuticals business in North America.  He returned to Johnson & Johnson in 2008 as Company Group Chairman for Ethicon, Inc.  In September 2009, he was appointed Worldwide Chairman of the Medical Devices & Diagnostics segment. In January 2011, he was named Vice Chairman of Johnson & Johnson’s Executive Committee. Mr Gorsky became Chief Executive Officer in April, 2012 and Chairman of the Board in December, 2013.

A longtime advocate of diversity and inclusion, Mr Gorsky has been named one of the “100 Most Inspiring Leaders” by Pharma Voice.  He is the Executive Sponsor of two Johnson & Johnson employee resource groups, the Women’s Leadership Initiative and the Veteran’s Leadership Council.  He is also a member of the Business Council and the Business Roundtable. He was recently given the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award, as well as an Honorary Doctorate from Thomas Jefferson University in Philadelphia. 

Mr Gorsky holds a Bachelor of Science degree from the US Military Academy at West Point, NY, and spent six years in the US Army, finishing his military career with the rank of Captain. He earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.

Stefano Pessina

Stefano Pessina

Executive Vice Chairman and CEO
Walgreens Boots Alliance

Stefano Pessina is Executive Vice Chairman and Chief Executive Officer of Walgreens Boots Alliance, having been appointed as a Non-Executive Director of Walgreens in August 2012.  Prior to this, he was Executive Chairman of Alliance Boots from July 2007.  Mr Pessina previously served as Executive Deputy Chairman of Alliance. Prior to the merger of Alliance UniChem and Boots plc, Mr Pessina was Executive Deputy Chairman of Alliance UniChem, previously having been its Chief Executive for three years through December 2004. Mr Pessina was appointed to the Alliance UniChem Board in 1997 when UniChem merged with Alliance Santé, the Franco-Italian pharmaceutical wholesale group which he established in Italy in 1977. Mr Pessina also serves on the Board of Directors of Galenica AG, a publicly-traded Swiss healthcare group, and a number of private companies.

Peter  Bach

Peter Bach

Director, Center for Health Policy and Outcomes
Memorial Sloan Kettering Cancer Center

Dr Peter Bach is a physician, epidemiologist, writer, and recognized expert in healthcare policy whose work has been regularly featured in major scientific and lay press outlets such as the NEJM, JAMA, and the New York Times. He is the Director, and currently holds the titles of Member in the Department of Epidemiology and Biostatistics and Attending Physician in the Department of Medicine at Memorial Sloan Kettering. He has also been a Senior Scholar at the International Agency for Research on Cancer since 2008.

Dr Bach is a member of the Institute of Medicine’s Board on Health Care Services and National Cancer Policy Forum and the Committee on Performance Measurement of the National Committee on Quality Assurance; he is also the Chair of the Center for Medicare and Medicaid Services Technical Expert Panel, which works to develop quality measures for PPS-exempt cancer hospitals. He has been inducted into the American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He also serves on the Board of Advisors of the University of Michigan Cancer Center and on the World Economic Forum, and is a member of the Clinton Global Initiative. Previously, Dr Bach was a member of the Institute of Medicine’s Committee on Geographic Variations and the Chair of a multi-society evidence-based guideline development committee on lung cancer screening. He also served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006

Dr Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar.

David Cutler

David Cutler

Otto Eckstein Professor of Applied Economics
Harvard University

David Cutler has developed an impressive record of achievement in both academia and the public sector. He is currently the Otto Eckstein Professor of Applied Economics in the Department of Economics and was named Harvard College Professor in 2014.  Professor Cutler holds secondary appointments at the Kennedy School of Government and the School of Public Health. He served as Assistant Professor of Economics from 1991 to 1995, was named John L. Loeb Associate Professor of Social Sciences in 1995, and received tenure in 1997. Professor Cutler was a key advisor in the formulation of the recent cost control legislation in Massachusetts, and is one of the members of the Health Policy Commission created to help reduce medical spending in that state. Author of Your Money Or Your Life: Strong Medicine for America's Health Care System, published by Oxford University Press, this book, and Professor Cutler's ideas, were the subject of a feature article in the New York Times Magazine, The Quality Cure, by Roger Lowenstein. Cutler's most recent book, The Quality Cure, pursues these themes. Professor Cutler received an AB from Harvard University (1987) and a PhD in Economics from MIT (1991)

Kenneth L. Davis

Kenneth L. Davis

President and CEO
Mount Sinai Health System

Kenneth L. Davis is the President and CEO of the Mount Sinai Health System in New York City, one of the largest integrated health systems in the nation, which is renowned for providing outstanding medical care to the diverse communities it serves, as well as for its significant global outreach. The Health System encompasses the Icahn School of Medicine at Mount Sinai and seven hospital campuses, and has a large, regional ambulatory footprint. For the decade prior to his appointment as leader of the Health System in 2013, Dr Davis served as President and CEO of The Mount Sinai Medical Center. Under his direction, Mount Sinai successfully launched a robust era of innovation in research, education, and clinical care. As a neurobiologist, Dr Davis’s pioneering research in Alzheimer’s disease led the U.S. Food and Drug Administration to approve three of the first four drugs on the market for the treatment of Alzheimer’s disease. A member of the Institute of Medicine of the National Academy of Sciences, he has published more than 500 papers and received numerous grants and awards, including the George H. W. Bush Lifetime of Leadership Award from Yale University, where he was an undergraduate.  In 2014, Dr Davis was appointed as a trustee of the Aspen Institute.

Jonathan Emms

Jonathan Emms

Senior Vice President, Global Health and Value
Pfizer
Sarah Emond

Sarah Emond

Chief Operating Officer
Institute for Clinical and Economic Review (ICER)

Sarah Emond is the first appointed Chief Operating Officer of Institute for Clinical and Economic Review (ICER). In this role, she is responsible for the strategic planning and operations of ICER. She brings with her over 15 years of experience in the business. Most recently was Principal at SKE Communications, a health policy and communications consultancy, and also served as the Manager of Corporate Communications at the commercial-stage biopharmaceutical company, Oscient Pharmaceuticals. Ms Emond began her communications career as an Account Executive with Feinstein Kean Healthcare and worked as a Clinical Research Coordinator at Beth Israel Deaconess Medical Center.

A graduate of the Heller School for Social Policy and Management at Brandeis University, Ms Emond holds a Master of Public Policy degree with a concentration in health policy.  She also received a Bachelor’s degree in Biological Sciences from Smith College.

Joseph Fifer

Joseph Fifer

President and CEO
Healthcare Financial Management Association

Joseph Fifer is President and CEO of the Healthcare Financial Management Association (HFMA). HFMA provides the resources healthcare organizations need to achieve sound fiscal health in order to provide excellent patient care. With more than 40,000 members, HFMA is the nation's leading membership organization of healthcare finance executives and leaders. Prior to assuming his position with HFMA in June 2012, Mr Fifer spent 11 years as Vice President of Hospital Finance at Spectrum Health, in Grand Rapids, Michigan. He also spent time with McLaren Health Care Corporation, Flint, Michigan, as Vice President of Finance and Ingham Regional Medical Center, Lansing, Michigan, as Senior Vice President of Finance and Chief Financial Officer. Mr Fifer started his career with nine years at Ernst and Young, also in Michigan.

Scott Gottlieb

Scott Gottlieb

Resident Scholar
American Enterprise Institute

Scott Gottlieb is a practicing physician and Resident Fellow at the American Enterprise Institute. Dr Gottlieb previously served as FDA Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Advisor to the FDA Commissioner and as the FDA’s Director of Medical Policy Development. He also worked on implementation of the Medicare Drug Benefit as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he supported policy work on quality improvement and the agency’s coverage process, particularly related to new medical technologies. In 2013 he was appointed by the Senate Majority Leader to serve on the Federal Health Information Technology Policy Committee, which advises the Department of Health and Human Services on health IT. Dr Gottlieb is a contributor to the editorial page of the Wall Street Journal and a guest commentator on the cable financial news channel CNBC. He is currently a Venture Partner at the venture capital firm New Enterprise Associates and a director to several life science companies, including Daiichi Sankyo US. He also serves as a member of GlaxoSmithKline’s Product Investment Board. Dr Gottlieb is a Clinical Assistant Professor at the NYU School of Medicine and completed a residency in internal medicine at the Mount Sinai Hospital in New York. He is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.

Ron Gutman

Ron Gutman

President and CEO
HealthTap

Ron Gutman is Founder and CEO of HealthTap .He is widely recognized as a thought leader in digital health and innovation and frequently presents at health and technology conferences, including TED, Health 2.0, and Fortune Tech Brainstorm (among many others). His articles on the future of mobile and digital health have been published in respected media outlets such as Forbes and the Huffington Post. Mr Gutman has also been featured in the national press about HealthTap and the future of health in the US and globally, including on CNBC (The Disrupters), CNN, NBC, The Washington Post (Innovations), The New York Times, Forbes, WIRED, Bloomberg and others.

A serial, accomplished entrepreneur, Mr Gutman has built mobile and online health applications that have profitably served hundreds of millions of people and saved tens of thousands of lives. As a graduate student at Stanford University, he organized and led a multidisciplinary group of faculty and graduate students conducting research in personalized health and in the design of ways to help people live healthier, happier lives. The group's work resulted in the implementation of one of the most acclaimed population health and wellbeing engagement programs in the nation, still in use today, BeWell@Stanford. Additionally, Mr Gutman is an angel investor and advisor to health and technology companies, Rock Health (The first Interactive Health Incubator), Stanford’s Medicine X, and Harvard Medical School's SMArt Initiative ("Substitutable Medical Apps, reusable technologies"). Additionally, he serves as the Curator of TEDx Silicon Valley and wrote the successful TED Book SMILE: The Astonishing Power of a Simple Act.

Sachin Jain

Sachin Jain

Chief Medical Officer
CareMore Health System

Sachin H. Jain is Chief Medical officer at CareMore Health System, an innovative health plan and care delivery system subsidiary of Anthem, Inc.  In this role, he has operational responsibility for 700 clinical staff and 24 care centers.  He is charged with developing and leading a multi-year strategy to expand next-generation care management/care delivery model nationally. 

Prior to joining CareMore, Dr Jain was Chief Medical Information and Innovation Officer at Merck & Co, where he developed global partnerships to leverage health data to improve patient health.  He also served as an attending hospitalist physician at the Boston VA-Boston Medical Center and lecturer in healthcare policy at Harvard Medical School.

From 2009-2011, Dr Jain pursued government service at the US Department of Health and Human Services, where he was senior advisor to the administrator of the Centers for Medicare and Medicaid Services (CMS) and helped launch the Center for Medicare and Medicaid Innovation (CMMI). He also served as special assistant to the National Coordinator for Health Information Technology at the Office of the National Coordinator for Health Information Technology (ONC), supporting the agency’s implementation of the HITECH Provisions of the Recovery Act and meaningful use.

Dr Jain graduated magna cum laude from Harvard College with a BA in Government, and continued on to earn his MD from Harvard Medical School and MBA from Harvard Business School. While completing his medical residency at Brigham and Women’s Hospital, he maintained a faculty appointment at the Harvard Business School and remains affiliated as a senior institute associate at the school’s Institute for Strategy and Competitiveness. He is board certified in internal medicine by the American Board of Internal Medicine.  He is Co-Founder and Co-Editor-in-Chief of the Elsevier journal Healthcare: The Journal of Delivery Science and Innovation.

Lisa Joldersma

Lisa Joldersma

Vice President, Policy and Research
Pharmaceutical Research and Manufacturers of America (PhRMA)

Lisa Joldersma is Vice President for Policy and Research at PhRMA, the Pharmaceutical Research and Manufacturers of America.  She works on behalf of the nation’s leading research-based biopharmaceutical companies to sustain and improve access to medicines in government programs and the private insurance market.  Ms Joldersma has nearly 20 years of health law and policy experience that spans both government and private industry. Immediately prior to joining PhRMA, she worked for the Blue Cross and Blue Shield Association representing the largest name in commercial health insurance on Medicare and Medicaid policy issues.  Before that, she worked for many years as a senior advisor for legislative policy at the Centers for Medicare & Medicaid Services. Her tenure spanned two Administrations, both Republican and Democrat, and placed Ms Joldersma at the center of two landmark pieces of legislation: the Medicare Modernization Act of 2003 and the Patient Protection and Affordable Care Act of 2010. Ms Joldersma is a graduate of the University of Michigan Law School and Hope College (Holland, MI). 

Laura Kaiser

Laura Kaiser

Executive Vice President and Chief Operating Officer
Intermountain Healthcare

Laura Kaiser is Executive Vice President and Chief Operating Officer for Intermountain Healthcare, an integrated, not-for-profit health system recognized as a leader in high clinical quality and sustainable costs. Kaiser is responsible for healthcare delivery and operations for the system’s 22 hospitals, as well as its Medical Group with 200+ Clinics and 1300+ employed physicians, its Clinical Programs, and its Institute for Healthcare Leadership. Prior to Intermountain, Ms Kaiser was President and CEO of Sacred Heart Health System in Pensacola, Florida, President of the Daughters of Charity Foundation and Regional Executive for Ascension Health. Ms Kaiser earned MBA and MHA degrees from Saint Louis University and a BS from the University of Missouri. She is a Fellow of the American College of Healthcare Executives and serves on several boards including The Catholic Diocese of Salt Lake City Finance Council, Huntsman-Intermountain Cancer Care Program, Salt Lake Chamber Board of Governors, the Scottsdale Institute, Westminster College and the Women’s Leadership Institute.

Amy Landucci

Amy Landucci

Global Head, Digital Medicines
Novartis Pharmaceuticals

Amy Landucci is the Global Head, Digital Medicines at Novartis Pharmaceuticals. The first executive of the company to ever hold this role, Ms Landucci and her team are responsible for defining the company’s digital strategy and strengthening cross-divisional digital medicines activities that impact everything from clinical trials to patient engagement. As part of her directive, Ms Landucci has spearheaded the creation of Novartis’ Digital Acceleration Laboratory, which leverages the latest digital technologies to accelerate the speed of R&D. She also drives strategic efforts to partner with external organizations that complement Novartis’ internal work. Ms Landucci joined the Novartis Pharmaceutical Division in 2004, having previously worked at Accenture. Since then she held roles of increasing responsibility in Novartis’ US Commercial IT function, including being appointed CIO for the Over-the-Counter (OTC) division in 2012, until she was appointed to her current position at the start of 2015.

Jeff Lindsay

Jeff Lindsay

Executive Vice President and Chief Operating Officer
Novant Health

Jeff Lindsay is Executive Vice President and Chief Operating Officer of Novant Health, where he is responsible for operational performance and strategic growth of the health system. Mr Lindsay has worked in healthcare for more than twenty years and has been part of Novant Health since 1996. Prior to taking up his current role in 2014, Mr Lindsay most recently served as President of Novant Health Forsyth Medical Center and Chief Executive Officer of the Winston-Salem and eastern North Carolina markets. He began his career at Novant Health as Vice President of Cardiovascular Services and has since served in a numerous leadership positions, including President of Presbyterian Hospital Huntersville, President of Rowan Regional Medical Center and Chief Operating Officer of the Triad region. Mr Lindsay serves on the North Carolina Hospital Association as Chairman of the Board and is a member of the Winston-Salem Alliance. Lindsay is also currently serving on the board of directors for the Forsyth Country Day School, Hospice and Palliative Care Center, Senior Services of Winston-Salem and the Arts Council of Winston-Salem and Forsyth County. Mr Lindsay holds a Bachelor of Science in Business Administration and Political Science from Auburn University and a Master of Science in Health Administration from the University of Alabama at Birmingham.

Demetrius Maraganore

Demetrius Maraganore

Medical Director
Neurological Institute, NorthShore University HealthSystem

Demetrius M. Maraganore is the Ruth Cain Ruggles Chairman of the Department of Neurology at NorthShore University HealthSystem and Medical Director of the NorthShore Neurological Institute. He is a Clinical Professor of Neurology at the University of Chicago.  With respect to digital health, Dr Maraganore directs NorthShore’s Center for Brain Health, applying advanced electronic medical record structured clinical documentation support tools, prediction models, and other digital health technologies to prevent Alzheimer’s disease.  He is the Principal Investigator of the Agency for Healthcare Research and Quality funded study Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record.  That study aims to create a national Neurology Practice Based Research Network which shares electronic medical record tools and data in support of comparative effectiveness research, and to incorporate into the electronic medical record subgroup based adaptive design tools to support pragmatic trials and precision medicine at the point of care.

David Miller

David Miller

Senior Vice President, Global Market Access
Biogen

David Miller has nearly 25 years of executive and operational roles in the biopharmaceutical industry. He currently is Senior Vice President of Global Market Access at Biogen with responsibility for securing pricing, reimbursement and access of Biogen products worldwide. Prior to joining Biogen in 2011, he was an independent consultant delivering market access strategies on behalf of biopharmaceutical clients. He previously worked at Elan, holding roles as Vice President of Pharmacoeconomics, Managing Director, and Head of International Operations. Dr Miller began his pharmaceutical industry career in pharmacoeconomics at GlaxoSmithKline and assumed increasing responsibilities in US and ex-US roles towards becoming Vice President of Global Health Outcomes. Dr Miller is the author or co-author of more than 70 scientific publications and is a frequent speaker on industry policy issues related to pricing, reimbursement and access. He is Director on the National Pharmaceutical Council Board of Directors, is a member of advisory boards at the University of Maryland Baltimore, University of Washington and Tufts University, and a board member of the Walther Foundation, a charitable organization supporting youth education. He served as a Director on the Board of Directors of Elan Pharma Ltd. and was Chair of the Board of Grants for the American Foundation for Pharmaceutical Education. He holds a degree in Pharmacy from the University of Iowa and earned his PhD in Pharmacy Administration at the University of Maryland Baltimore where he studied Health Economics and Policy.

Harold Miller

Harold Miller

President and CEO
Center for Health Quality and Payment Reform

Harold Miller is the President and CEO of the Center for Healthcare Quality and Payment Reform (CHQPR), a national policy center that facilitates improvements in healthcare payment and delivery systems. Professor Miller is a nationally-recognized expert on healthcare payment and delivery reform; he has given invited testimony to Congress on how to reform healthcare payment, has worked in more than 40 states and metropolitan regions to help physicians, hospitals, employers, health plans, and government agencies design and implement payment and delivery system reforms, and has authored numerous reports on health care payment and delivery reform. Professor Miller is one of eleven appointed members of the federal Physician-Focused Payment Model Technical Advisory Committee that was created by Congress in 2015 to advise the Secretary of Health and Human Services on the creation of alternative payment models. He also serves as Adjunct Professor of Public Policy and Management at Carnegie Mellon University.

Jeff Myers

Jeff Myers

President and CEO
Medicaid Health Plans of America

Jeff Myers is the President and CEO of Medicaid Health Plans of America (MHPA), the leading trade association for Medicaid managed care organizations. He serves as the spokesperson for the managed Medicaid industry before Congress, the executive branch, states, and the media, demonstrating the value of Medicaid managed care and leading advocacy efforts for industry policy priorities. Prior to MHPA, Mr Myers was Senior Vice President of Policy and Government Relations at the American Health Care Association, represented the pharmaceutical companies Cephalon, Biogen Idec, Pharmacia, and Hoffman-LaRoche before the legislative and executive branches, and served as US Representative Fred Upton’s Legislative Director and Health Staff for the Energy and Commerce Health Subcommittee. He also worked for US. Representative Alex McMillan where he led Health Staff during consideration of the Health Security Act. Mr Myers received his MBA from Duke’s Fuqua School of Business and his Bachelor’s degree from Rhodes College.

Anne Phelps

Anne Phelps

Principal, US Healthcare Regulatory Leader
Deloitte

Anne Phelps is a Deloitte Advisory Principal in the Life Sciences and Health Care practice of Deloitte & Touche LLP. She has over twenty-seven years of health care policy experience in a broad range of legislative and regulatory issues. Ms Phelps serves as a strategic business advisor to numerous health care stakeholders - including providers, payers, employers, life sciences companies, and investors - to help them navigate the complex health care regulatory environment and how it will impact their organizations. This involves understanding the regulatory landscape, interpreting the impact on the various stakeholders, and helping organizations scenario plan, formulate priorities, and execute their strategies.

Prior to her career in professional services, Ms Phelps served in the Bush Administration as a Special Assistant to the President as the Chief Health Policy Advisor to the President for the Domestic Policy Council and as the Executive Director of the 2004 Republican National Platform Committee. Earlier in her career, Ms Phelps worked on Capitol Hill in the United States Senate and at the National Institutes of Health in a variety of health policy and legislative roles.

David Ricks

David Ricks

Senior Vice President and President, Lilly Bio-Medicines
Eli Lilly and Company

Dave Ricks is Senior Vice President of Eli Lilly and Company and President of Lilly Bio-Medicines. As head of the Biomedicines of division of Lilly, Mr Ricks oversees Lilly’s PRA (pricing, reimbursement, and access) function, as well as the therapeutic areas of neuroscience, cardiovascular, urology, musculoskeletal and autoimmunity. In his position, Mr Ricks plays a critical role in a partnership between Lilly and Anthem. Through the partnership, the two companies are working together to remove legal and regulatory barriers with the goal of improving health outcomes and solutions for patients, customers and caregivers. Mr Ricks joined Lilly in 1996 as a Business Development Associate, and has held several management roles in US Marketing and Sales before moving to Lilly Canada, where he served as Director of Pharmaceutical Marketing, as National Sales Director, and then as General Manager. He then was named President and General Manager of Lilly China before becoming president of Lilly USA in 2009. Before joining Lilly, Mr Ricks worked for Hewlett-Packard and IBM. Mr Ricks earned a Bachelor’s degree in Business from Purdue University and a Master’s degree in Business Administration from Indiana University. He serves on the Board of Governors for the Riley Children’s Foundation.

Leonard Schleifer

Leonard Schleifer

President and CEO
Regeneron

Leonard Schleifer is the longest serving CEO of a major US biotechnology company. He founded Regeneron Pharmaceuticals in 1988, with Eric Shooter, a leading researcher in the area of nerve growth factors, and Alfred G. Gilman, who received the 1994 Nobel Prize in Medicine for Physiology. Prior to starting Regeneron, he was Assistant Professor at the Cornell University Medical College in the Departments of Neurology and Neurobiology. Dr Schleifer, together with George Yancopoulos, Chief Scientific Officer and a Founding Scientist of the company, have grown Regeneron over 25 years from a tiny start-up to an over $40 billion market cap company with four FDA-approved drugs - PRALUENT ® (alirocumab) Injection, EYLEA ® (aflibercept) Injection, ZALTRAP ® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST ® (rilonacept) Injection. Under Dr Schleifer’s leadership, the company has established key business collaborations and developed industry- leading technologies for drug discovery and development, resulting in a robust pipeline of monoclonal antibody candidates in areas of high unmet need. In 2011, Dr Schleifer was selected as New York Region Entrepreneur of the Year in Healthcare by Ernst & Young and was appointed by New York Governor Andrew Cuomo Co-Chair of the Mid-Hudson Region Economic Development Council.
Dr Schleifer graduated Phi Beta Kappa and summa cum laude from Cornell University and was awarded his MD and PhD in Pharmacology from the University of Virginia. He is Certified in Neurology by the American Board of Psychiatry and Neurology.

Jeffrey Schwartz

Jeffrey Schwartz

Principal
Bain Capital Private Equity

Jeffrey Schwartz is a Principal at Bain Capital Private Equity, a leading global private investment firm with approximately $75 billion in assets under management. He has significant experience in private equity investing, with specialized focus in the healthcare sector. Since joining the firm in 2004, Mr. Schwartz has been actively involved in and served on the Board of Directors for a wide spectrum of prominent healthcare companies in which Bain Capital has made investments. These businesses include Air Medical Group Holdings, a leading provider of community-based air ambulance services, CRC Health, a leading behavioral healthcare service provider, Lake Region Medical, a leading provider of fully integrated outsourced manufacturing and engineering services to the medical device industry; and QuVa Pharma, Inc., a newly formed national platform for sterile compounding pharmacy services. Mr Schwartz also serves as a Trustee of the Commonwealth School. Prior to joining Bain Capital Private Equity, Mr Schwartz served as an Equity Research Analyst at Lehman Brothers, where he was focused on the aerospace and defense industries. Mr Schwartz received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Yale University with a BA in Economics.

Bruno Villetelle

Bruno Villetelle

Chief Digital Officer
Takeda Pharmaceuticals

Bruno Villetelle is Chief Digital Officer in Takeda Pharmaceuticals International AG, a position he has held since 2014. Prior to this he was with Nestlé S.A., where, in his role as Vice President and Global Head of Digital Services he steered the development and operation of all digital services across the Nestlé group. For Mr Villetelle, first and foremost, digital health goes “beyond the pill” to provide trusted information and connections that people need…in the way they need it…to radically improve the customer experience and patient care. As a digital thought leader and innovator experienced driving digital acceleration programs in global organizations, Mr Villetelle leads a team of dedicated believers and evangelists who recognize that a changing health care market requires thinking in new ways to deliver patient-centric solutions.

Daphne Zohar

Daphne Zohar

Co-Founder and CEO
PureTech

Daphne Zohar is a Co­-Founder and the Chief Executive Officer of PureTech and a member of the Board. A successful entrepreneur, Ms Zohar created PureTech, assembling a leading team to help implement her vision for the Company, and attracting over $450 million to the Company and its operating companies. Ms Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including BioWorld, MIT's Technology Review, the Boston Globe, and Scientific American. She sits on the boards of PureTech, the Sync Project, Akili Interactive Labs, Follica, Karuna and Tal. She also sits on the Technology Development Fund Advisory Board at Children's Hospital Boston and is an Editorial Advisor to Xconomy, a national news company.

fallback

Chair & Moderators (3)

Andrew Ward

Andrew Ward

Energy Editor
Financial Times

Andrew Ward is the FT’s Energy Editor, leading global coverage of the oil and gas industry, power generation and related policy and geopolitical issues. Before taking up his current role in June 2016, Ward was Pharmaceuticals Correspondent, reporting on life sciences, medical technology and healthcare.

Prior to this, Ward was UK News Editor, leading the news desk responsible for the FT’s coverage of UK politics, policy and economics. Previously, Ward served the FT in a number of foreign reporting roles. He was the Nordic bureau chief responsible for coverage of eight countries – Sweden, Norway, Finland, Iceland, Denmark and the three Baltic states of Latvia, Estonia and Lithuania.

Ward has also been the White House correspondent, during which role he covered the George W. Bush administration and the 2008 presidential election campaign. Before moving to Washington, Ward covered business and politics in the US south-east as Atlanta Correspondent. Between 2001 and 2004, he served as Seoul Correspondent, reporting on North and South Korea.

Ward joined the FT in 1999 as a graduate trainee in London and was appointed Media Correspondent in 2000. Ward received his B.A. in Politics and Modern History from the University of Manchester, UK.

Follow Andrew Ward on twitter: @andrew_ward1

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Mitchell  Morris

Mitchell Morris

Global Life Sciences and Healthcare Industry Leader
Deloitte

Mitchell Morris is the global leader for the life sciences and health care industry as well as the global leader for the health care sector of Deloitte Touche Tohmatsu Limited (Deloitte). Additionally, he is Vice Chair and sector leader for health care providers for Deloitte in the United States. Dr Morris has more than 30 years of health care experience in consulting, health care administration, research, technology, education, and clinical care. Dr Morris’s focus has been on health systems, academic organizations, and government agencies, assisting them with the development and implementation of strategies around reform, operations, clinical programs and quality, IT and finance. Earlier, he served as a Senior Vice President of Health Systems and Chief Information Officer at MD Anderson Cancer Center where he was also Professor in Gynecologic Oncology and in Health Services Research.

Photos from 2016 Summit

FT US Healthcare & Life Sciences Summit Photos

To view photos from the 2016 Summit, click here.

fallback

Agenda - 12th May

  • 8:00am
    Registration and Breakfast
  • 9:00am
    Opening Remarks from the Chair

    Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 9:05am
    Opening Keynote Address

    Alex Gorsky, Chairman of the Board and CEO, Johnson & Johnson

  • 9:30am
    Healthcare and Politics: Obamacare and Beyond - What Will the Election Mean for Healthcare in the US?

    The November 2016 US Presidential election is widely considered to be the most significant healthcare event in the US in the next 18 months. Change looks likely to remain a constant in the US healthcare market, irrespective of who is elected. If the Democratic party maintain power, it will still mean a change of stewardship of the Affordable Care Act (ACA), and the new administration may revisit some key aspects of the law, opening up the opportunity for providers, payers and other stakeholders to put forward alternative approaches for consideration. Republicans, meanwhile, have rallied around a call to make the election a ‘referendum on Obamacare’ with plans to repeal ACA if elected, and replace it with ‘something better’. What could a change of political leadership mean for healthcare? How reversible are the reforms given the extension in healthcare coverage achieved and polls suggesting a general public satisfaction with the law? What could it mean for key provisions of existing law such as evidence-based medicine and for 21st Century Cures? What are the alternative approaches on offer which could 'fix' America’s broken healthcare system?

    Session Keynote: David Cutler, Otto Eckstein Professor of Applied Economics, Harvard University

    Joseph Fifer, President and CEO, Healthcare Financial Management Association
    Anne Phelps, US Healthcare Regulatory Leader, Deloitte
    Jeffrey Schwartz, Principal, Bain Capital Private Equity

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 10:20am
    Networking Break
  • 10:40am
    Drug Pricing: The Dawn of A New Era?

    The escalating cost of new drugs has captivated America and sparked a clamor for change. In recent years, an increasing number of drugs, notably for hard-to-treat conditions, have debuted at high prices, with some advanced drugs costing an average of $100,000 or more for a year’s supply. Payers and providers are fighting back with calls for drugs to be reimbursed on the basis of their value. And the tide is turning for the US freewheeling drug pricing model in other respects too. Recent developments show the direction of change, including the growing prominence of European-style HTA models such as ICER, a not-for-profit research organization examining the value of drugs and setting benchmarks for drug prices, as well as the inclusion of cost considerations in American Society of Clinical Oncology (ASCO) guidelines for cancer drug prescribing by physicians. Are current high costs justified, or have prices become divorced from their value and benefits? Is the US premium Pricing model sustainable? What could be the implications of lower prices for The economic model of the industry? Is The Institute for Clinical and Economic Review (ICER) the new The National Institute for Health and Care Excellence (NICE), and UK-style drug rationing a taste of things to come in the US? How can the current impasse over escalating prices be addressed, and how can pharma companies and payers become part of the solution?

    Peter Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
    Jonathan Emms, Senior Vice President, Global Health and Value, Pfizer
    Sarah Emond, Chief Operating Officer, Institute for Clinical and Economic Review (ICER)
    Jeff Myers, President and CEO, Medicaid Health Plans of America
    Leonard Schleifer, President and CEO, Regeneron

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times 

  • 11:30am
    Better Together? How will Consolidation and Convergence Transform the Healthcare Industry?

    The twin forces of convergence and consolidation continue to play out in the healthcare industry with billions of dollars of M&A activity, partnerships and new alliances across the entire healthcare spectrum as stakeholders, payers, medical device companies, pharma companies and providers tussle for position and pricing power for the value-based world of healthcare which lies ahead. Advocates of consolidation and convergence claim it will help wring greater efficiencies from the 18% of GDP the US currently spends on healthcare and enable healthcare companies to become more efficient and to invest the resources needed to service patients with high quality care at affordable costs. Critics maintain it will result in higher premiums and reduced choice for customers. What will be the impact of consolidation and convergence on the industry and on patients? Will merged groups pass on savings to consumers? Will customers gain better bargaining power and better choice of hospitals and physicians? To what extent might the growth of public exchanges products, and growing power of healthcare consumerism act as a counterweight to consolidation among payers and providers?  

    Session Keynote: Jeff Lindsay, Executive Vice President and Chief Operating OfficerNovant Health

    Kenneth L. Davis, President and CEO, Mount Sinai Health System
    Scott Gottlieb, Resident Scholar, American Enterprise Institute
    Lisa Joldersma, Vice President, Policy and Research, Pharmaceutical Research and Manufacturers of America (PhRMA)

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 12:15pm
    Lunch
  • 1:20pm
    Keynote Session

    Tom Frieden, Director, Centers for Disease Control and Prevention (CDC)

  • 1:45pm
    Keynote Presentation

    Dave Ricks, Senior Vice President, Eli Lilly and Company; President, Lilly Bio-Medicines

  • 1:55pm
    Value Gets Real: Navigating the Shift to Value Based Care and Outcomes Based Pricing

    The move to value is accelerating in the US. Accountable Care Organizations (ACOs) are proliferating. The adoption of value-orientated payment models are on the increase nationally as health insurers and pharmaceutical benefit managers strive to tie payments for drugs to how well they perform, and as they compete to meet the growing demand of employers for value. An estimated 40% of healthcare dollars are now in some way tied to value against only 11% only a few years ago. Are we now on the cusp of major change - a tipping point when the focus on value considerations start to make a significant contribution to the transformation of the healthcare system? What needs to happen for that to happen - for instance greater involvement and pressure for employers? What have been the experiences of value-based contracting from pioneering healthcare and life science companies to date? What are the shortfalls of the current system? How is value being defined, and what changes and improvements are needed to jolt the system into real change?

    Sachin Jain, Chief Medical Officer, CareMore Health System
    Laura Kaiser, Executive Vice President and Chief Operating Officer, Intermountain Healthcare
    David Miller, Senior Vice President, Global Market Access, Biogen
    Harold Miller, President and CEO, Center for Health Quality and Payment Reform

    Moderator: Mitchell Morris, Global Life Sciences and Healthcare Industry Leader, Deloitte

  • 2:55pm
    What Next for Digital Health?

    How will digital health change the nature of competition in the healthcare industry? Will the industry's most successful players come from outside the traditional industry walls, as new entrants from the world of retail, consumer industries and IT, for instance, enabled by technology and strong consumer acumen, close the gaps in current healthcare infrastructure and bring innovative ideas and business models to make healthcare more convenient and affordable? Or will traditional healthcare and life science companies own the day through their industry knowledge, expertise and ability to navigate complex legal and regulatory issues? Who will be the healthcare industry’s next Amazon? How will the power of ‘big data’ be harnessed to create new technologies, products and services to diagnose, treat and prevent disease? How will the future of the industry unfurl? In this concluding session of the conference, our panel of leading industry experts will discuss how digital will transform healthcare in the years ahead.

    Ron Gutman, President and CEO, HealthTap
    Amy Landucci, Global Head, Digital Medicines, Novartis Pharameuticals
    Demetrius Maraganore, Medical Director, Neurological Institute, NorthShore University HealthSystem
    Bruno Villetelle, Chief Digital Officer, Takeda Pharmaceuticals
    Daphne Zohar, Co-Founder and CEO, PureTech

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 3:55pm
    Closing Keynote Address and Interview

    Stefano Pessina, Executive Vice Chairman and CEO, Walgreens Boots Alliance

  • 4:20pm
    Closing Remarks from the Chair

Why Attend?

  • Keep abreast of the latest political maneuvering and the implications of the 2016 US Election for healthcare and life sciences
  • Discover whether the tide is turning for the US freewheeling drug pricing model
  • Share experiences with pioneers and peers as the stage is set for the transition to value based care and outcomes based pricing
  • Debate the implications of industry consolidation and convergence on patient choice and costs 
  • Embrace opportunities for networking and collaboration with peers from across the sector
fallback

Who Attends?

This event is for: CEOs, CFOs, CIOs, Chief Medical Officers, Chief Strategy Officers, Heads of R&D, Emerging Markets, Consumer Health, Government Relations, Pricing, Regulation, Market Access, etc. and other senior-level executives in the following sectors:

  • Pharmaceuticals, Biotechnology, Generic and Specialty Pharmaceutical companies
  • Medical Devices and Diagnostics
  • Investment (Fund Managers, Venture Capitalists, Private Equity firms, Investment Bankers, IP Groups)
  • Legal Counsel
  • Healthcare IT (Patient records, data, mobile healthcare applications, social media)
  • Regulation

OUR PREVIOUS ATTENDEES INCLUDED:

Aetna
AHIP             
BioPharm Insight            
Blackstone Healthcare Partners
Cigna
Eastern Long Island Hospital
EDventure Holdings
Ernst & Young
GE Healthcare
GSK
Intermountain Healthcare
Mayo Clinic
Memorial Sloan Kettering Cancer Center
North Shore-LIJ Health Center
Novartis
PhRMA
Rivermend Health
Sandoz 
Towers Watson
Verizon Enterprise Solutions

Abbott
AstraZeneca
Berkley Life Sciences
Cardinal Health Canada
Cold Spring Harbor Laboratory
Covance
Edelman
Eli Lilly & Company
Ferring Pharmaceuticals
GNS Healthcare
Interbrand Health
Johnson & Johnson
Medtronic
New York Genome Center
New York State Department of Financial Services
Pfizer
Quest Diagnostics
Sanofi
Takeda Pharmaceuticals 
UK Trade and Investments

fallback

Why Sponsor?

  • Gain access to senior decision makers across the full spectrum of the healthcare industry
  • Brand alignment with the FT and its unrivalled credibility
  • Demonstrate thought leadership around the current critical issues affecting the healthcare sector
  • Benefit from sustained international visibility through our advertising and marketing campaigns
fallback

Venue

The Metropolitan Club
One East 60th Street (at Fifth Avenue)
New York 10022

United States of America

Tel: +1 212-838-7400

fallback

Nearby Accommodations

We have put together a unique HotelMap that shows hotel deals at nearby hotels. To view, click here.

fallback

With the support of (1)

About Life Sciences and Health Care at Deloitte

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability..

*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.

Sponsors (2)

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Novant Health is an integrated network of physician clinics, outpatient facilities and hospitals that provides high quality healthcare to more than 4 million patients annually. Named in 2016 by Becker’s Hospital Review as one of the nation’s 150 best places to work in healthcare, Novant Health has nearly 1,400 physicians and 24,000 employees at nearly 530 locations, including 13 medical centers. In 2015, the health system provided more than $706 million in community benefit, including charity care and services. IMS Health named Novant Health as one of the nation’s top 20 integrated delivery networks while Diversity MBA has recognized the organization as one of the 50 best places for women and managers of diverse backgrounds to work. Headquartered in Winston-Salem, North Carolina, Novant Health is committed to making healthcare remarkable for patients and communities.

For more information, please visit our website at NovantHealth.org. You can also follow us on Twitter and Facebook.

Supporting Partners (4)

The Health Care M&A Information Source is a comprehensive data source that is devoted to health care mergers and acquisitions for the serious analyst and investor. This publication alerts you to developments in every key segment of the health care services and technology markets, including behavioral health care, biotechnology, eHealth, home health & hospice, hospitals, laboratories, long-term care, managed care, medical devices, pharmaceuticals, physician medical groups, rehabilitation and more. You won’t find more comprehensive information anywhere else. Sign up for a risk-free trial today!

The Hudson Valley Economic Development Corporation (HVEDC) is the region’s leading economic development organization, providing strategic guidance and business services to thousands of companies, entrepreneurs, academicians and governments. HVEDC manages multiple, award-winning industry cluster initiatives including NY BioHud Valley, Hudson Valley EDs & MEDs, Hudson Valley Food & Beverage Alliance, Hudson Valley 3D Printing (HV3D) and Hudson Valley PLAY. From developing the region’s first biotech incubator to opening the nation’s first MakerBot 3D Printing Innovation Center to launching the largest craft beverage summit in New York, HVEDC is taking the Hudson Valley economy to new heights.

The New York eHealth Collaborative (NYeC) is a not-for-profit organization, working in partnership with the New York State Department of Health to improve healthcare for all New Yorkers through health information technology (health IT).

Founded in 2006 by healthcare leaders, NYeC receives funding from state and federal grants to serve as the focal point for health IT in the State of New York. NYeC develops policies and standards, assists healthcare providers in making the shift to electronic health records, and coordinates the creation of the Statewide Health Information Network of New York (SHIN-NY), a network to connect healthcare providers statewide.

PE provides its audience of over 100,000 pharmaceutical and biopharmaceutical executives with the analysis of business, strategy and government regulations that no one else provides. We go beyond the news and provide in-depth analysis to help executives navigate through the maze of policy and business challenges that face this industry. We do it through the review of the issues, interviews and roundtable discussions with thought leaders and business leader. We provide this information that the pharmaceutical and biopharmaceutical community wants in the multiplatform format that they want it in; print, online, webinars, white papers, video, native content and newsletters.

CONTACT US

Funmbi Adenubi
Delegate Booking and Registration Enquiries
Financial Times
Meredith Vachon
Media Partner & Press Inquiries
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Tim Powell
Sponsorship Opportunities
Financial Times